Literature DB >> 19853978

The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine.

Francisco J Ramos-Lima1, Victoria Moneo, Adoración G Quiroga, Amancio Carnero, Carmen Navarro-Ranninger.   

Abstract

Despite some initial research that reported a lack of activity of trans geometry, complexes with general formula trans-[PtCl2(L)(L')] exhibit an important cytotoxic activity in cisplatin-sensitive and resistant cell lines. Based on the proposed mechanism of action for the trans-platinum compounds, they might form DNA adducts initiating a DNA-damage response and ultimately ending in the activation of the p53 protein. In the present work, we have studied the biochemical properties of the trans-[PtCl2(isopropylamine)(L)] complexes (where L is 3- or 4-(hydroxymethyl)-pyridine) against several cell lines and the relationship between cytotoxicity and the protein p53. Both complexes showed different antitumoral properties depending on the presence or absence of protein p53 in isogenic colon carcinoma HCT116 cell lines. Cell cycle studies with the complexes in these cell lines were performed to investigate their antitumoral activity. Apoptosis was observed to be launched from G1 or G2/M accumulations. Confocal microscopy showed the different behaviour of isogenic tumoral cell lines treated with the trans-platinum complexes. Our data suggest that small differences in the carrier ligands could play an important role in the overall biological effects. The body of the research regarding structure-activity relationships such as the different position of groups in the carrier ligands will provide new rational basis for the design of new platinum antitumor drugs. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853978     DOI: 10.1016/j.ejmech.2009.09.035

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

1.  Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.

Authors:  Robert F Murphy; Edina Komlodi-Pasztor; Robert Robey; Frank M Balis; Nicholas P Farrell; Tito Fojo
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

2.  Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.

Authors:  Lana Filipovic; Sandra Arandelovic; Nevenka Gligorijevic; Ana Krivokuca; Radmila Jankovic; Tatjana Srdic-Rajic; Gordana Rakic; Zivoslav Tesic; Sinisa Radulovic
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

3.  Geranylgeranylacetone attenuates cisplatin-induced reductions in cell viability by suppressing the elevation of intracellular p53 content without heat shock protein induction.

Authors:  Motofusa Hasegawa; Kazuhiro Ishiguro; Takafumi Ando; Hidemi Goto
Journal:  Nagoya J Med Sci       Date:  2012-02       Impact factor: 1.131

4.  In Vitro and in vivo Evaluation of Electrochemotherapy with trans-platinum Analogue trans-[PtCl2(3-Hmpy)2].

Authors:  Simona Kranjc; Maja Cemazar; Gregor Sersa; Janez Scancar; Sabina Grabner
Journal:  Radiol Oncol       Date:  2017-09-14       Impact factor: 2.991

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.